1 Aug 2022 14:58
1 August 2022
Medica Group Plc
Issue of Equity and Total Voting Rights
Further to the Block Listing Application announcement on the 30 June 2022, Medica Group PLC (LSE:MGP, "Medica" or the "Company"), the UK and Ireland market leader in the provision of teleradiology services, has allotted and issued 4,799 of the 8,399 ordinary shares of 0.2 pence each in the capital of the Company ("New Ordinary Shares"). The New Ordinary Shares have been used to satisfy options under the Company's 2019 Sharesave Scheme. The New Ordinary Shares will rank pari passu with the Company's existing shares.
Following the issue of the New Ordinary Shares, the Company have 122,433,635 Ordinary Shares in issue. There are no Ordinary Shares held in treasury. Therefore, the Company hereby confirms that, following the issue of the New Ordinary Shares, the total number of voting rights in the Company are 122,433,635. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Medica Group Plc: Stuart Quin, Chief Executive Officer Richard Jones, Chief Financial Officer
| +44 (0)33 33 111 222
|
FTI Consulting Victoria Foster Mitchell Sam Purewal
| +44 (0)20 3727 1000 |
Liberum (Joint Broker) Phil Walker Richard Lindley
| +44 (0)20 3100 2000 |
Numis (Joint Broker) Freddie Barnfield Duncan Monteith Euan Brown
| +44 (0)20 7260 1000
|
About Medica Group PLC
Medica (LSE:MGP) is an international provider of high-quality telemedicine services. It is the market leader in teleradiology in the UK and Ireland, working with more than 100 NHS Trusts and HSE hospitals in Ireland, in addition to private hospitals, insurance groups and diagnostic imaging companies. Its network of consultant radiologists, radiographers and specialist doctors interpret and report MRI, CT, ultrasound and X-ray images on behalf of healthcare providers, using Medica's bespoke, secure technology platform for fast and responsive delivery. The company's core services include NightHawk, an urgent, out-of-hours offering available to clients 24/7 with dedicated pathways for stroke and major trauma, and Elective, for routine reporting.
In Ireland, Medica carries out patient scanning, as well as reporting, and runs a diabetic retinopathy screening programme for the National Screening Service. Through its US business, RadMD, Medica provides global pharmaceutical and biotech companies, as well as contract research organisations with specialist imaging services for clinical trials.
For more information, please visit: www.medicagroupplc.com